In patients with type 2 diabetes, hypertension is associated with a range of adverse outcomes including cardiovascular disease (CVD) and premature mortality. Consequently, clinical guidelines recommend that patients with type 2 diabetes undertake measures to maintain a blood pressure at or below target levels. Among the interventions advocated to assist in achieving these targets, most guidelines recommend a reduced intake of sodium, as dietary sodium intake is positively correlated with blood pressure levels in the general population. Moreover, in patients with type 2 diabetes,salt restriction confers a modest reduction in blood pressure, and salt supplementation reduces the antihypertensive efficacy of blood pressure-lowering agents in the short term. However, the precise relationship between salt intake and mortality in patients with type 2 diabetes has not been previously explored. It is widely assumed that any blood pressure lowering associated with reduced dietary salt intake may be translated into protection from end-organ damage in the context of diabetes. However, there is also evidence that reduced sodium intake is associated with activation of metabolic and neurohormonal pathways, including the sympathetic nervous system and the renin-angiotensinaldosterone system (RAAS), as well as increases in total and LDL cholesterol and reduced peripheral insulin sensitivity. In the context of type 2 diabetes, each of these factors may offset or even outweigh gains achieved from blood pressure lowering. Hence, in this talk I discuss with Clinical importance and meta-analysis of study of sodium intake in diabetic patients